Myocardial infarction associated with erenumab: a case report - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Year : 2022

Myocardial infarction associated with erenumab: a case report

Abstract

Background: Monoclonal antibodies acting on the calcitonin gene related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab. Case: A 57-year-old woman with a familial history of coronaropathy, was first treated with erenumab 70 mg for 6 months, then increased to 140 mg. Almost five months after, the patient presented chest pain, increased troponin and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI. Conclusion: Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate exams to measure the burden of coronary atherosclerosis, if necessary.
Fichier principal
Vignette du fichier
Pharmacotherapy - 2022 - Perino - Myocardial infarction associated with erenumab A case report.pdf (2.24 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-03687314 , version 1 (03-06-2022)

Identifiers

Cite

Justine Perino, Virginie Corand, Elise Laurent, Hélène Théophile, Ghada Miremont‐salamé, et al.. Myocardial infarction associated with erenumab: a case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022, Online ahead of print. ⟨10.1002/phar.2706⟩. ⟨inserm-03687314⟩
17 View
30 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More